TipRanks
Advertisement
Advertisement

XERS Stock Latest News

Lundbeck exploring acquisition of Xeris, Bloomberg reports
The FlyLundbeck exploring acquisition of Xeris, Bloomberg reports
3d ago
XERS
Xeris jumps 13% to $11.12 after Bloomberg report of Lundbeck interest
PremiumThe Fly
Xeris jumps 13% to $11.12 after Bloomberg report of Lundbeck interest
3d ago
XERS
Xeris Biopharma tells Bloomberg ‘not for sale’
PremiumThe Fly
Xeris Biopharma tells Bloomberg ‘not for sale’
3d ago
XERS
Lundbeck has expressed interest in acquiring Xeris, Bloomberg reports
PremiumThe Fly
Lundbeck has expressed interest in acquiring Xeris, Bloomberg reports
3d ago
XERS
Xeris Biopharma management to meet virtually with Craig-Hallum
PremiumThe Fly
Xeris Biopharma management to meet virtually with Craig-Hallum
18d ago
XERS
Xeris Biopharma price target raised to $16 from $12 at Leerink
PremiumThe FlyXeris Biopharma price target raised to $16 from $12 at Leerink
22d ago
XERS
Xeris Biopharma price target raised to $16 from $12 at Leerink
Premium
The Fly
Xeris Biopharma price target raised to $16 from $12 at Leerink
22d ago
XERS
Xeris Highlights XP-8121 Strategy and Growth Roadmap
Premium
Company Announcements
Xeris Highlights XP-8121 Strategy and Growth Roadmap
23d ago
8K
XERS
Xeris Biopharma hosts webinar on XP-8121 development program
PremiumThe Fly
Xeris Biopharma hosts webinar on XP-8121 development program
23d ago
XERS
Xeris Biopharma price target raised to $12 from $9 at Barclays
PremiumThe Fly
Xeris Biopharma price target raised to $12 from $9 at Barclays
1M ago
XERS
Xeris Biopharma: Buy Rating Reiterated on Strong Recorlev Momentum and Raised 2026 Outlook; $10 Price Target Maintained
PremiumRatings
Xeris Biopharma: Buy Rating Reiterated on Strong Recorlev Momentum and Raised 2026 Outlook; $10 Price Target Maintained
2M ago
XERS
Xeris Pharmaceuticals’ Earnings Call Highlights Growth Momentum
PremiumCompany Announcements
Xeris Pharmaceuticals’ Earnings Call Highlights Growth Momentum
2M ago
XERS
Xeris Biopharma reports Q2 EPS (18c), consensus $0.00
PremiumThe FlyXeris Biopharma reports Q2 EPS (18c), consensus $0.00
2M ago
XERS
Xeris Biopharma tightens FY26 revnue view $385M-$390M, consensus $385.94M
Premium
The Fly
Xeris Biopharma tightens FY26 revnue view $385M-$390M, consensus $385.94M
2M ago
XERS
Xeris Biopharma Eliminates 2028 Convertible Notes Via Exchanges
Premium
Company Announcements
Xeris Biopharma Eliminates 2028 Convertible Notes Via Exchanges
3M ago
8K
XERS
Xeris Pharmaceuticals appoints new director and board chair
PremiumCompany Announcements
Xeris Pharmaceuticals appoints new director and board chair
3M ago
8K
XERS
Xeris Biopharma appoints CEO John Shannon as chair of the board
PremiumThe Fly
Xeris Biopharma appoints CEO John Shannon as chair of the board
3M ago
XERS
Xeris Biopharma announces notice of allowance from USPTO for Keveyis patent
PremiumThe Fly
Xeris Biopharma announces notice of allowance from USPTO for Keveyis patent
4M ago
XERS
Xeris Biopharma Announces Debt Reduction via Note Exchanges
PremiumCompany Announcements
Xeris Biopharma Announces Debt Reduction via Note Exchanges
4M ago
8K
XERS
Xeris Biopharma announces private exchange of convertible notes
PremiumThe FlyXeris Biopharma announces private exchange of convertible notes
4M ago
XERS
Xeris Biopharma Shareholders Elect Directors and Ratify Auditor
Premium
Company Announcements
Xeris Biopharma Shareholders Elect Directors and Ratify Auditor
4M ago
8K
XERS
Xeris Pharmaceuticals Signals Profitable Growth Acceleration
Premium
Company Announcements
Xeris Pharmaceuticals Signals Profitable Growth Acceleration
5M ago
XERS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >